Showing 3361-3370 of 3448 results for "".
- Layoffs at Medicis top 300, with 117 staffers chosen to stayhttps://practicaldermatology.com/news/20130104-layoffs_at_medicis_top_300_with_117_staffers_chosen_to_stay/2459648/The layoff toll at Medicis Pharmaceutical has topped 300, the Phoenix Business Journal reports. Valeant Pharmaceuticals ($VRX), which wrapped up its buyout of the Arizona-based skin drug company last week, has cut 319 staffers--and kept 117--as it integrates Medicis into its own dermatology operatio
- Xeljanz Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121118-xeljanz_approved_for_rheumatoid_arthritis/2459679/The FDA recently approved Xeljanz (tofacitinib) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to, or who are intolerant of, methotrexate. The decision comes ahead of the product's prescription drug user fee goal date of Nov
- Provectus Presents Data on PV-10 in Combination with Systemic Chemotherapyhttps://practicaldermatology.com/news/20121029-provectus_presents_data_on_pv-10_in_combination_with_systemic_chemotherapy/2459688/Provectus Pharmaceuticals, Inc. presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. PV-10 is Provectus Pharmaceuticals' novel oncology drug design
- LEO Pharma's Taclonex Topical Suspension Approved for Body Plaqueshttps://practicaldermatology.com/news/20121029-leo_pharma_receives_fda_approval_for_taclonex_topical_suspension/2459689/LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is
- Celgene to Present Data From Abraxane Melanoma Studyhttps://practicaldermatology.com/news/20121009-celgene_to_present_data_from_abraxane_melanoma_study/2459712/Results from a late-stage clinical trial by Celgene Corp. show its cancer drug Abraxane slows the progression of melanoma. The trial compared Abraxane and dacarbazine in 529 patients with melanoma that had metastasized. The company says that patients treated with Abraxane had greater progression-fre
- Stiefel/GSK Receives FDA Approval of Sorilux Foam, 0.005%https://practicaldermatology.com/news/20121002-stiefel_receives_fda_approval_of_sorilux_foam_0005/2459719/The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005% from Stiefel/GSK. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psor
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi
- Nomir Medical Submits 510(k) Application to FDA for Onychomycosishttps://practicaldermatology.com/news/20120911-nomir_medical_announces_510k_application_to_fda_for_onychomycosis/2459742/Nomir Medical Technologies, Inc. submitted a 510(k) application to the US Food and Drug Administration (FDA) for the indication of temporary increase of clear nail in patients with onychomycosis (toenail fungus). This 510(k) submission to FDA
- Abbott 2Q Profit Beats Expectations, Humira Sales Growhttps://practicaldermatology.com/news/20120802-abbott_2q_profit_beats_expectations_humira_sales_grow/2459757/Abbott Laboratories announced that second-quarter earnings narrowly beat estimates, fueled by the continued growth of its drug Humira. The company said net income for the quarter declined to $1.75 billion, or $1.08 per share, from $1.94 b
- Syneron Receives FDA Clearance for elōs Plushttps://practicaldermatology.com/news/20120712-syneron_receives_fda_clearance_for_els_plus/2459774/Syneron Medical Ltd. (NASDAQ: ELOS) received US Food and Drug Administration (FDA) clearance for elōs Plus, a multi-platform system featuring the company's proprietary elōs technology of optical energy and bi-polar radiofrequency. The FDA clearance follo